Changchun GeneScience Pharmaceutical
As of the edition of 20 October 2026, Changchun GeneScience Pharmaceutical runs 24 drugs, 2 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 17 |
| Stopped | 2 |
| Status not established | 3 |
| Total | 24 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tislelizumab | Ends 2036 (computed from the first US licence) | 2 |
| Aumolertinib | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CSF3R Granulocyte colony-stimulating factor receptor | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Changchun GeneScience Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 7 trials led
- Urinary and reproductive: 6 trials led
- Bones, joints and muscles: 5 trials led